Sequencing of ACVR1/ALK2 in patient derived DIPG cell lines

Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.

Report outlining how genomic DNA was extracted from patient derived diffuse intrinsic pontine glioma cell lines*, PCR was used to amplify commonly mutated exons of ACVR1, and the regions Sanger sequenced. * Lines HSJD-GBM-002, SU-DIPG-IV, HSJD-DIPG-006, HSJD-DIPG-007, HSJD-DIPG-011, SU-DIPG-XXI

Related Organizations

University of Oxford
United Kingdom

Keywords

pcr, dipg, alk2, patient derived cell lines, diffuse intrinsic pontine glioma, genomic dna extraction, acvr1, sanger sequencing

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average